Psoriatic Arthritis

Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

In this Healio video, Philip J. Mease, MD, discusses ongoing clinical trials in psoriatic arthritis and data presented at ACR Convergence 2023, as well as upcoming research.

Izokibep achieved the primary endpoint of ACR50 response in a phase 2b/3 psoriatic arthritis trial, and demonstrated sustained, “deepening” benefit in hidradenitis suppurativa, according to top-line data from its manufacturer.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

Fatigue among patients with psoriasis with or without psoriatic arthritis was associated with joint paint, itch and, to a lesser extent, disease severity, according to a study.

SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.

SCOTTSDALE, Ariz. — Understanding how guidelines and recommendations are formed can make them “most helpful” in clinical practice, according to a presentation at the Basic and Clinical Immunology for the Busy Clinician symposium.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the TYK2 inhibitor deucravacitinib from the Maui Derm 2024 meeting, examining its use as a treatment for psoriasis.